TherapeuticsMD (TXMD) Cash from Financing Activities (2011 - 2023)

TherapeuticsMD (TXMD) has 13 years of Cash from Financing Activities data on file, last reported at $2.0 million in Q4 2023.

• Quarterly Cash from Financing Activities rose 101.79% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$108.2 million (up 54.0% YoY) and the FY2023 annual result came in at $3.2 million, up 101.34% from the prior year.
• Cash from Financing Activities rose to $2.0 million in Q4 2023, from -$1000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $111.7 million in Q2 2019 to a low of -$120.0 million in Q2 2022.
• A 5-year average of $9.2 million and a median of $890500.0 in 2021 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2020 — Cash from Financing Activities jumped 48669.82% — and 2022, when it tumbled 28137.38%.
• Tracing TXMD's Cash from Financing Activities over 5 years: stood at $77.0 million in 2019, then slumped by 58.84% to $31.7 million in 2020, then tumbled by 95.73% to $1.4 million in 2021, then tumbled by 8373.84% to -$111.9 million in 2022, then soared by 101.79% to $2.0 million in 2023.
• The last three Cash from Financing Activities figures came in at $2.0 million (Q4 2023), -$1000.0 (Q3 2023), and -$111.9 million (Q4 2022), per Business Quant data.